Teva Pharma (TEVA) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Piper Jaffray Remains Sidelined on Teva Pharma (TEVA) Following 1Q - PT to $58
May 10, 2016 8:04 AM EDTPiper Jaffray maintained a Neutral rating on Teva Pharma (NYSE: TEVA), and cut the price target to $58.00 (from $59.00), following the company's 1Q earnings report. TEVA reported a non-GAAP EPS of $1.20 on revenues of $4.81B, ahead of the Street's estimates of $1.17 and $4.77B, respectively. Management noted that companies with older, more commodity-focused portfolios should expect... More
Teva Pharma (TEVA) Attractive, Well Managed Business; Price Cut to $75 - Mizuho
May 10, 2016 6:45 AM EDTMizuho analyst, Irina Koffler maintained her Buy rating after Teva Pharma (NYSE: TEVA) effectively defended its generics business and eased concerns about the AGN deal closure. A bottom line beat also helped the stock. We think this is a well-managed business and valuation... More
